Abstract：
UNASSIGNED: Despite advancements, invasive fungal infections (IFI) still carry high mortality rates, often exceeding 30%. The challenges in diagnosis, coupled with limited effective antifungal options, make managing IFIs complex. Antifungal drugs are essential for IFI management, but their efficacy can be diminished by drug-drug interactions and pharmacokinetic variability. Therapeutic Drug Monitoring (TDM), especially in the context of triazole use, has emerged as a valuable strategy to optimize antifungal therapy.
UNASSIGNED: This review provides current evidence regarding the potential benefits of TDM in IFI management. It discusses how TDM can enhance treatment response, safety, and address altered pharmacokinetics in specific patient populations.
UNASSIGNED: TDM plays a crucial role in achieving optimal therapeutic outcomes in IFI management, particularly for certain antifungal agents. Preclinical studies consistently show a link between therapeutic drug levels and antifungal efficacy. However, clinical research in mycology faces challenges due to patient heterogeneity and the diversity of fungal infections. TDM\'s potential advantages in guiding Echinocandin therapy for critically ill patients warrant further investigation. Additionally, for drugs like Posaconazole, assessing whether serum levels or alternative markers like saliva offer the best measure of efficacy is an intriguing question.
UNASSIGNED: This review provides current evidence regarding the potential benefits of TDM in IFI management. It discusses how TDM can enhance treatment response, safety, and address altered pharmacokinetics in specific patient populations.
UNASSIGNED: TDM plays a crucial role in achieving optimal therapeutic outcomes in IFI management, particularly for certain antifungal agents. Preclinical studies consistently show a link between therapeutic drug levels and antifungal efficacy. However, clinical research in mycology faces challenges due to patient heterogeneity and the diversity of fungal infections. TDM\'s potential advantages in guiding Echinocandin therapy for critically ill patients warrant further investigation. Additionally, for drugs like Posaconazole, assessing whether serum levels or alternative markers like saliva offer the best measure of efficacy is an intriguing question.
摘要：
■尽管有进步，侵袭性真菌感染（FI）仍然具有很高的死亡率，往往超过30%。诊断的挑战，加上有效的抗真菌药物选择有限，使管理国际金融机构变得复杂。抗真菌药物对于国际金融机构管理至关重要，但药物间相互作用和药代动力学变异性会降低其疗效。治疗药物监测（TDM），特别是在三唑使用的情况下，已成为优化抗真菌治疗的有价值的策略。
■本综述提供了有关TDM在国际金融机构管理中的潜在益处的最新证据。它讨论了TDM如何增强治疗反应，安全,并解决特定患者人群中药代动力学的改变。
■TDM在实现FI管理中的最佳治疗结果中起着至关重要的作用，特别是某些抗真菌剂。临床前研究一致显示治疗药物水平和抗真菌功效之间的联系。然而,由于患者异质性和真菌感染的多样性,真菌学临床研究面临挑战.TDM在指导棘球红素治疗危重患者方面的潜在优势值得进一步研究。此外,像泊沙康唑这样的药物，评估血清水平或唾液等替代标志物是否能提供最佳疗效指标是一个有趣的问题.
■本综述提供了有关TDM在国际金融机构管理中的潜在益处的最新证据。它讨论了TDM如何增强治疗反应，安全,并解决特定患者人群中药代动力学的改变。
■TDM在实现FI管理中的最佳治疗结果中起着至关重要的作用，特别是某些抗真菌剂。临床前研究一致显示治疗药物水平和抗真菌功效之间的联系。然而,由于患者异质性和真菌感染的多样性,真菌学临床研究面临挑战.TDM在指导棘球红素治疗危重患者方面的潜在优势值得进一步研究。此外,像泊沙康唑这样的药物，评估血清水平或唾液等替代标志物是否能提供最佳疗效指标是一个有趣的问题.
